APA (7th ed.) Citation

RM, K., F, M., E, G., TJ, S., Y, Ü., J, K., . . . M, S. (2025). Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: Results from the multicenter real-world ARON-1 study. Cancer immunology, immunotherapy : CII, 74(12), 374. https://doi.org/10.1007/s00262-025-04230-w

Chicago Style (17th ed.) Citation

RM, Kopp, et al. "Real-world Evidences on Adjuvant Pembrolizumab for Renal Cell Carcinoma: Results from the Multicenter Real-world ARON-1 Study." Cancer Immunology, Immunotherapy : CII 74, no. 12 (2025): 374. https://doi.org/10.1007/s00262-025-04230-w.

MLA (9th ed.) Citation

RM, Kopp, et al. "Real-world Evidences on Adjuvant Pembrolizumab for Renal Cell Carcinoma: Results from the Multicenter Real-world ARON-1 Study." Cancer Immunology, Immunotherapy : CII, vol. 74, no. 12, 2025, p. 374, https://doi.org/10.1007/s00262-025-04230-w.